Skip to main content

Table 4 Angiographic and PCI characteristics during initial PCI

From: In-stent restenosis of drug-eluting stents: clinical presentation and outcomes in a real-world scenario

ParameterTotal (n = 106)ACS cohort (n = 68)Non-ACS cohort (n = 38)P value
Lesion type   0.427
 A51 (48.1%)29 (42.7%)22 (57.9%) 
 B28 (26.4%)19 (27.9%)9 (23.7%) 
 C27 (25.5%)20 (29.4%)7 (18.4%) 
Calcification14 (13.2%)7 (10.3%)7 (18.4%)0.358
Disease burden   0.627
 Single-vessel disease55 (51.9%)38 (55.9%)17 (44.7%) 
 Double-vessel disease33 (31.1%)18 (26.5%)15 (39.5%) 
 Triple-vessel disease18 (17.0%)12 (17.6%)6 (15.8%) 
Details of PCI    
 No. of stents1.3 ± 0.61.3 ± 0.61.3 ± 0.60.923
 Stent length27.0 ± 8.728.2 ± 8.724.6 ± 8.60.124
 Stent diameter2.92 ± 0.342.93 ± 0.362.90 ± 0.310.712
 Pre-dilation63 (59.4%)43 (63.2%)20 (52.6%)0.541
 Post-dilation43 (40.5%)27 (39.7%)16 (42.1%)0.944
DES type   0.683
 Paclitaxel3 (2.8%)3 (4.4%) 
 Sirolimus70 (66.1%)46 (67.6%)24 (63.2%) 
 Everolimus21 (19.8%)12 (17.7%)9 (23.7%) 
 Zotarolimus12 (11.3%)7 (10.3%)5 (13.1%) 
Time to ISR26.8 ± 2524.5 ± 2431.9 ± 30.10.481
  1. ACS acute coronary syndrome, DES drug-eluting stent, PCI percutaneous coronary intervention